Richard Kim, MD

GI Oncology Now

<p>Richard Kim, MD, Moffitt Cancer Center, gives an overview of a study that compared HERIZON-BTC-01 with an external real-world comparator cohort to determine the survival outcomes of zanidatamab compared to chemotherapy in patients with previously treated HER2-positive biliary tract cancer.<p>Dr. Kim discusses how these results may influence the design of future prospective studies or regulatory pathways, and touches on the observed survival advantage with zanidatamab in the context of previous second-line options for HER2-positive BTC.</p></p>


Christopher Lieu, MD

ATOMIC: Adjuvant Chemo Alone, With Atezo for Patients With Stage III dMMR Colon Cancer

Colorectal Cancer

Lauren Dembeck, PhD

BREAKWATER Trial Shows Practice-Changing Survival Benefit in BRAF V600E–Mutant mCRC

ATOMIC: Atezolizumab Plus Chemotherapy as New SOC in Stage III dMMR Colon Cancer

Latest News

HERIZON-BTC-01 vs a Real-World Control Arm: Comparing Zanidatamab With Chemotherapy for Biliary Tract Cancer

Bile Duct Cancer

Dr. Richard Kim discusses survival outcomes of zanidatamab compared to chemotherapy in patients with previously treated HER2+ biliary tract cancer at the 2025 ASCO Annual Meeting.

HERIZON-BTC-01 vs a Real-World Control Arm: Comparing Zanidatamab With Chemotherapy for BTC

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

GU Oncology Now

Lung Cancers Today

Cancer Nursing Today

DocWire News

MashupMD

Bile Duct

Colorectal

Esophageal

Gastric

GEP-NETs

GIST

Liver

Pancreatic

Conference Coverage

Video Insights

Roundtable